170 related articles for article (PubMed ID: 29140422)
21. Clinical Outcomes of Metastatic Poor Prognosis Germ Cell Tumors: Current Perspective From a Referral Center.
Necchi A; Farè E; Vullo SL; Giannatempo P; Raggi D; Nicolai N; Piva L; Biasoni D; Catanzaro M; Torelli T; Stagni S; Maffezzini M; Verzoni E; Grassi P; Procopio G; Pizzocaro G; Mariani L; Salvioni R
Clin Genitourin Cancer; 2015 Aug; 13(4):385-391.e1. PubMed ID: 25726505
[TBL] [Abstract][Full Text] [Related]
22. Methotrexate, paclitaxel, ifosfamide, and cisplatin in poor-risk nonseminomatous germ cell tumors.
Pectasides D; Pectasides E; Papaxoinis G; Xiros N; Kamposioras K; Tountas N; Economopoulos T
Urol Oncol; 2010; 28(6):617-23. PubMed ID: 19110454
[TBL] [Abstract][Full Text] [Related]
23. Improved outcomes in metastatic germ cell cancer: results from a large cohort study.
Hentrich M; Debole J; Jurinovic V; Gerl A
J Cancer Res Clin Oncol; 2021 Feb; 147(2):533-538. PubMed ID: 32772232
[TBL] [Abstract][Full Text] [Related]
24. Impact of primary metastatic bone disease in germ cell tumors: results of an International Global Germ Cell Tumor Collaborative Group G3 Registry Study.
Oing C; Oechsle K; Necchi A; Loriot Y; De Giorgi U; Fléchon A; Daugaard G; Fedyanin M; Faré E; Bokemeyer C
Ann Oncol; 2017 Mar; 28(3):576-582. PubMed ID: 27993806
[TBL] [Abstract][Full Text] [Related]
25. Predicting outcomes in female germ cell tumors using a modified International Germ Cell Cancer Collaborative Group classification system to guide management.
Liu YL; Manning-Geist BL; Knezevic A; Deng L; Bromberg M; Funt SA; Meisel JL; Zivanovic O; Roche KL; Sonoda Y; Gardner GJ; Grisham RN; O'Cearbhaill RE; Tew WP; Abu-Rustum NR; Chi DS; Aghajanian C; Feldman DR
Gynecol Oncol; 2023 Mar; 170():93-101. PubMed ID: 36669327
[TBL] [Abstract][Full Text] [Related]
26. Progression-free and overall survival in patients with relapsed/refractory germ cell tumors treated with single-agent chemotherapy: endpoints for clinical trial design.
Feldman DR; Patil S; Trinos MJ; Carousso M; Ginsberg MS; Sheinfeld J; Bajorin DF; Bosl GJ; Motzer RJ
Cancer; 2012 Feb; 118(4):981-6. PubMed ID: 21792865
[TBL] [Abstract][Full Text] [Related]
27. Treatment outcome of metastatic testicular cancer at a single institution in Japan, a country with low incidence of germ cell tumor.
Kawai K; Hinotsu S; Oikawa T; Sekido N; Hattori K; Miyanaga N; Hasegawa Y; Kojima H; Shimazui T; Akaza H
Jpn J Clin Oncol; 2006 Nov; 36(11):723-30. PubMed ID: 17082218
[TBL] [Abstract][Full Text] [Related]
28. DNA damage measured in blood cells predicts overall and progression-free survival in germ cell tumour patients.
Sestakova Z; Kalavska K; Smolkova B; Miskovska V; Rejlekova K; Sycova-Mila Z; Palacka P; Obertova J; Holickova A; Hurbanova L; Jurkovicova D; Roska J; Goffa E; Svetlovska D; Chovanec M; Mardiak J; Mego M; Chovanec M
Mutat Res Genet Toxicol Environ Mutagen; 2020; 854-855():503200. PubMed ID: 32660824
[TBL] [Abstract][Full Text] [Related]
29. Long-Term Survival of Good-Risk Germ Cell Tumor Patients After Postchemotherapy Retroperitoneal Lymph Node Dissection: A Comparison of BEP × 3 vs. EP × 4 and Treating Institution.
Cary C; Jacob JM; Albany C; Masterson TA; Hanna NH; Einhorn LH; Foster RS
Clin Genitourin Cancer; 2018 Apr; 16(2):e307-e313. PubMed ID: 29104087
[TBL] [Abstract][Full Text] [Related]
30. Risk-Stratified Initial Salvage Therapy for Relapsed or Refractory Metastatic Germ Cell Tumors.
Narayan V; Gunnarsson O; Hwang WT; Squillante CM; Nathanson KL; Stadtmauer EA; Vaughn DJ
Clin Genitourin Cancer; 2016 Dec; 14(6):524-529. PubMed ID: 27083130
[TBL] [Abstract][Full Text] [Related]
31. Systemic inflammatory markers have independent prognostic value in patients with metastatic testicular germ cell tumours undergoing first-line chemotherapy.
Fankhauser CD; Sander S; Roth L; Gross O; Eberli D; Sulser T; Seifert B; Beyer J; Hermanns T
Br J Cancer; 2018 Mar; 118(6):825-830. PubMed ID: 29485982
[TBL] [Abstract][Full Text] [Related]
32. Late relapses (>2 years) in patients with stage I testicular germ cell tumors: predictive factors and survival.
Fedyanin M; Tryakin A; Kanagavel D; Bulanov A; Burova A; Figurin K; Fainshtein I; Sergeev U; Zakharova T; Garin A; Tjulandin S
Urol Oncol; 2013 May; 31(4):499-504. PubMed ID: 21803619
[TBL] [Abstract][Full Text] [Related]
33. Treatment results in children and adolescents with loco-regional recurrences of abdominal germ cell tumors (GCTs): a pilot-study with PEI chemotherapy and regional deep hyperthermia (RHT) in comparison to a matched cohort.
Wessalowski R; Blohm M; Calaminus G; Engert J; Harms D; Krause I; Kruck H; Grüttner HP; Pape H; Göbel U
Klin Padiatr; 1997; 209(4):250-6. PubMed ID: 9293458
[TBL] [Abstract][Full Text] [Related]
34. Development of a risk stratification system to guide treatment for female germ cell tumors.
Meisel JL; Woo KM; Sudarsan N; Eng J; Patil S; Jacobsen EP; Murali R; Gardner GJ; Bosl GJ; Aghajanian C; Feldman DR
Gynecol Oncol; 2015 Sep; 138(3):566-72. PubMed ID: 26115974
[TBL] [Abstract][Full Text] [Related]
35. Improved long term survival of patients with metastatic nonseminomatous testicular germ cell carcinoma in relation to prognostic classification systems during the cisplatin era.
Sonneveld DJ; Hoekstra HJ; van der Graaf WT; Sluiter WJ; Mulder NH; Willemse PH; Koops HS; Sleijfer DT
Cancer; 2001 Apr; 91(7):1304-15. PubMed ID: 11283931
[TBL] [Abstract][Full Text] [Related]
36. The Prognostic Value of Neutrophil-to-Lymphocyte Ratio in Metastatic Testicular Cancer.
Ribnikar D; Stukalin I; Bedard PL; Hamilton RJ; Jewett M; Warde P; Chung P; Anson-Cartwright L; Templeton AJ; Amir E; Hansen AR; Heng DYC; Lewin J
Curr Oncol; 2020 Dec; 28(1):107-114. PubMed ID: 33622996
[TBL] [Abstract][Full Text] [Related]
37. The impact of bleomycin on retroperitoneal histology at post-chemotherapy retroperitoneal lymph node dissection of good risk germ cell tumors.
Cary KC; Pedrosa JA; Kaimakliotis HZ; Masterson TA; Einhorn LH; Foster RS
J Urol; 2015 Feb; 193(2):507-12. PubMed ID: 25254937
[TBL] [Abstract][Full Text] [Related]
38. Germ Cell Tumors with Malignant Somatic Transformation: A Mayo Clinic Experience.
Scheckel CJ; Kosiorek HE; Butterfield R; Ho TH; Hilal T
Oncol Res Treat; 2019; 42(3):95-100. PubMed ID: 30820020
[TBL] [Abstract][Full Text] [Related]
39. Long-term follow-up of intensive chemotherapy followed by reduced-dose and reduced-field irradiation for intracranial germ cell tumor.
Takada A; Ii N; Hirayama M; Toyoda H; Matsubara T; Toyomasu Y; Kawamura T; Daimon T; Sakuma H; Nomoto Y
J Neurosurg Pediatr; 2018 Nov; 23(3):317-324. PubMed ID: 30497152
[TBL] [Abstract][Full Text] [Related]
40. Treatment Outcome in Patients with Primary Central Nervous System Germ Cell Tumour: Clinical Experience from a Regional Cancer Centre in North India.
Biswas A; Julka PK; Bakhshi S; Singh M; Rath GK
Pediatr Neurosurg; 2017; 52(4):240-249. PubMed ID: 28538229
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
